



**AMENDMENTS TO THE CLAIMS**

The following listing of claims replaces all prior versions presented in the application.


1 (previously presented): A compound or a pharmaceutically acceptable salt thereof represented by Formula (I):



wherein  $R^1$  represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aromatic heterocyclic group;  $n$  represents an integer of 0 to 3;  $X^1$  and  $X^2$  may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aromatic heterocyclic group; and formula (II):




represents formula (III):



wherein  $X-Y-Z$  represents  $R^2C=CR^3-NR^4$  (wherein  $R^2$ ,  $R^3$  and  $R^4$  may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aromatic

heterocyclic group),  $R^2C=N-NR^4$  (wherein  $R^2$  and  $R^4$  have the same meanings as defined above, respectively),  $R^4N-CR^3=CR^2$  (wherein  $R^2$ ,  $R^3$  and  $R^4$  have the same meanings as defined above, respectively), or  $R^4N-N=CR^2$  (wherein  $R^2$  and  $R^4$  have the same meanings as defined above, respectively) or formula (IV):



(IV)

wherein  $Xa--Ya--Za$  represents  $R^2HC-NR^3-CHR^4$  (wherein  $R^2$ ,  $R^3$  and  $R^4$  have the same meanings as defined above, respectively),  $R^2HC-NR^3-NH$  (wherein  $R^2$  and  $R^3$  have the same meanings as defined above, respectively), or  $NH-NR^3-CHR^4$  (wherein  $R^3$  and  $R^4$  have the same meanings as defined above, respectively).

2 (previously presented): The compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein  $R^1$  is substituted or unsubstituted lower alkyl.

3 (previously presented): The compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein  $R^3$  is substituted or unsubstituted aryl, or substituted or unsubstituted lower alkyl.

4 (previously presented): The compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein  $X^1$  is substituted or unsubstituted aralkyl and  $X^2$  is a hydrogen atom.

5 (previously presented): A Pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient.

6-13 (canceled).


14 (previously presented): A method for treating diabetes, which comprises administering an effective amount of the compound or a pharmaceutically acceptable salt thereof according to claim 1.

15 (previously presented): A method for treating diabetic complications, which comprises administering an effective amount of the compound or a pharmaceutically acceptable salt thereof according to claim 1.

16 (previously presented): A method for lowering blood glucose levels, which comprises administering an effective amount of the compound or a pharmaceutically acceptable salt thereof according to claim 1.

17 (previously presented): A method for stimulating secretion of insulin, which comprises administering an effective amount of the compound or a pharmaceutically acceptable salt thereof according to claim 1.

18 (previously presented): A compound represented by the formula selected from the group consisting of the following Formulas (1) to (10):



or a pharmaceutically acceptable salt thereof.

19 (previously presented): A method for treating diabetic complications, which comprises administering an effective amount of the compound or a pharmaceutically acceptable salt thereof according to claim 18.

20 (previously presented): A method for lowering blood glucose levels, which comprises administering an effective amount of the compound or a pharmaceutically acceptable salt thereof according to claim 18.

21 (previously presented): A method for stimulating secretion of insulin, which comprises administering an effective amount of the compound or a pharmaceutically acceptable salt thereof according to claim 18.

22 (new): A method for treating diabetes, which comprises administering an effective amount of the compound or a pharmaceutically acceptable salt thereof according to claim 18.